$CLYD · BEACON TOPCO, INC.
Beacon Topco filed an 8-K disclosing (1) a Second Amendment to the Clywedog Merger Agreement setting the closing date and End Date to October 31, 2026, and (2) positive final Phase 1b results for balomenib in type 2 diabetes. The 60-patient study showed placebo-adjusted HbA1c reductions of 0.77% at Week 12 and 0.70% at Week 16 — three months after the last dose of a three-week treatment course — with no drug-related serious adverse events. A Phase 2a study with a 12-week treatment course is expected to initiate in Q4 2026.
- Merger closing date amended to October 31, 2026 (or earlier by mutual agreement), with End Date also set to October 31, 2026.
- Phase 1b balomenib study: placebo-adjusted HbA1c reduction of 0.77% at Week 12 (p<0.01) and 0.70% at Week 16 (p<0.05) — three months after a
- No drug-related serious or severe adverse events; no therapy-related discontinuations in the 60-patient study.
- Phase 2a study with extended 12-week treatment course expected to initiate in Q4 2026.
- Preclinical ZDF rat data: HbA1c 5.9% in balomenib-treated vs 10.9% in vehicle controls 35 days post-dosing (p<0.001).
Price data unavailable.
Balomenib's durability signal — sustained glycemic improvement months after dosing stopped — hints at a disease-modifying mechanism, a rare profile in diabetes drug development.
The balomenib durability signal — sustained HbA1c reduction three months after a three-week course — is unusual in diabetes drug development, where most agents require continuous dosing. This differentiates from SGLT2 inhibitors and GLP-1 agonists.
Phase 1b glycemic endpoints were exploratory, not primary; the durability signal needs confirmation in the larger Phase 2a trial. Merger closing remains contingent on conditions being satisfied by October 31, 2026.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.